Drugs / Sodium enoxaparin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01308528 | Feb 2015 → Feb 2017 | venous thromboembolism | Cristália Produtos Químicos Farmacêuticos Ltda. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07124819 Comparator | Jul 2024 → Jan 2025 | osteoarthritis, hip, osteoarthritis, knee, venous thromboembolism | Avexima Diol LLC | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium enoxaparin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01308528 ↗ |